AML Breast Cancer CAR T-Cell Therapy Chronic Lymphocytic Leukemia EGFR+ Lung Cancer Follicular Lymphoma GI Cancers HCC HER2-Positive Breast Cancer Lung Cancer Lymphomas Mantle Cell Lymphoma MPNs Multiple Myeloma Ovarian Prostate Cancer Renal Cell Carcinoma Thyroid Cancers

View More Brain Cancer Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Cancers Head & Neck Cancers Hematology Leukemias Lung Cancer Lymphomas Melanoma Sarcoma Skin Cancers Thyroid Cancers

Brain Cancer Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Cancers Head & Neck Cancers Hematology Leukemias Lung Cancer Lymphomas Melanoma Sarcoma Skin Cancers Thyroid Cancers

News

Conferences

Conference Coverage Conference Listing

Media

All Videos Case-Based Peer Perspectives Expert Perspective Virtual Tumor Board Interviews Investigator Perspectives Medical World News Podcasts Precision Medicine

Publications

All Publications Evolving Paradigms Roundtable Meetings Spotlight Targeted Therapies in Oncology

CME/CE

Resources

Partners Precision Medicine Perspectives Press Releases

eNewsletter

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
Do Not Sell My Information
Privacy
Terms & Conditions

Featured Clinical Focus

AML
Breast Cancer
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
EGFR+ Lung Cancer
Follicular Lymphoma
GI Cancers
HCC
HER2-Positive Breast Cancer
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
MPNs
Multiple Myeloma
Ovarian
Prostate Cancer
Renal Cell Carcinoma
Thyroid Cancers

Clinical FocusSee All >

Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancers
Hematology
Leukemias
Lung Cancer
Lymphomas
Melanoma
Sarcoma
Skin Cancers
Thyroid Cancers

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
Do Not Sell My Information
Privacy
Terms & Conditions

Questions That Remain Regarding Combination, Sequencing With PARP Inhibitors

September 25, 2016

Patricia LoRusso, DO, PhD

Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.